Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
88 EUR | -0.23% | +0.35% | -1.96% |
Mar. 18 | AstraZeneca follows rival Boehringer in capping out-of-pocket costs for inhalers | RE |
Mar. 15 | Euroapi: production suspended in Brindisi | CF |
Sales 2024 * | 46.45B 50.5B | Sales 2025 * | 50.24B 54.61B | Capitalization | 110B 119B |
---|---|---|---|---|---|
Net income 2024 * | 7.34B 7.98B | Net income 2025 * | 8.68B 9.44B | EV / Sales 2024 * | 2.52 x |
Net Debt 2024 * | 6.96B 7.56B | Net Debt 2025 * | 2.42B 2.63B | EV / Sales 2025 * | 2.24 x |
P/E ratio 2024 * |
14.6
x | P/E ratio 2025 * |
12.4
x | Employees | 86,088 |
Yield 2024 * |
4.36% | Yield 2025 * |
4.73% | Free-Float | 87.77% |
Latest transcript on Sanofi
1 day | -0.23% | ||
1 week | +0.35% | ||
Current month | +0.13% | ||
1 month | +1.78% | ||
3 months | +0.34% | ||
6 months | -14.40% | ||
Current year | -1.96% |
Managers | Title | Age | Since |
---|---|---|---|
Paul Hudson
CEO | Chief Executive Officer | 56 | 19-08-31 |
Director of Finance/CFO | 59 | 18-09-30 | |
Nestle Frank
CTO | Chief Tech/Sci/R&D Officer | - | 16-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Patrick Kron
BRD | Director/Board Member | 70 | 14-04-30 |
Lise Kingo
BRD | Director/Board Member | 62 | 20-04-27 |
Gilles Schnepp
BRD | Director/Board Member | 64 | 20-05-21 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
6.31% | 5 M€ | +4.56% | ||
3.66% | 129 M€ | -.--% | - | |
3.55% | 264 M€ | +13.50% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-18 | 88 | -0.23% | 813,952 |
24-03-15 | 88.2 | -0.01% | 3,106,988 |
24-03-14 | 88.21 | -0.32% | 1,249,466 |
24-03-13 | 88.49 | +0.17% | 1,017,214 |
24-03-12 | 88.34 | +0.02% | 1,131,977 |
Real-time Euronext Paris, March 18, 2024 at 12:35 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.96% | 120B | |
+30.83% | 679B | |
+30.96% | 589B | |
+0.01% | 381B | |
+15.18% | 314B | |
+11.39% | 308B | |
+0.78% | 212B | |
-6.09% | 210B | |
-2.92% | 203B | |
-3.72% | 158B |